文章摘要

文章信息/Info

Title:: The effect of con-saponin of dioscoreae nipponicae on ozone- induced airway hyperresponsiveness and IL-17A expression in mice

作者:: 王爱利1; 2; 王悦1; 2; 郭佳1; 刘磊1; 李晶晶1; 邓林红1; 2△; 1.常州大学生物医学工程与健康科学研究院暨常州市呼吸医学工程重点实验室，常州 213164;2.常州大学制药与生命科学学院/护理学院，常州 213164

Author(s):: WANG Aili1; 2; WANG Yue1; 2; GUO Jia1; LIU Lei1; LI Jingjing1; DENG Linhong1; 2; 1.Institute of Biomedical Engineering and Health Sciences, Changzhou Key Laboratory of Respiratory Medical Engineering, Changzhou University, Changzhou 213164, China;2.School of Pharmaceutical Engineering and Life Science, School of Nursing, Changzhou University, Changzhou 213164

Keywords:: Airway hyperresponsiveness; Airway resistance; Con-saponin of dioscoreae nipponicae; Interleukin-17A; Asthma

摘要:: 穿山龙总皂苷是中药穿山龙的提取物，可抑制哮喘动物的气道炎症，但其是否对气道高反应性有影响未见报道。本研究为观察穿山龙总皂苷对气道高反应性动物模型的疗效，并初步探讨其机制，采用臭氧为诱导因素，分别建立急性、亚急性气道高反应性模型小鼠，通过肺功能仪检测气道阻力的变化，肺泡灌洗液中炎症细胞总数和分类计数在光学显微镜下检测。并采用ELISA法测定肺泡灌洗液和肺组织匀浆液中IL-17A水平，结果显示小鼠在臭氧应激下诱导发生气道高反应性和IL-17A表达上升等哮喘典型特征的变化，而雾化吸入穿山龙总皂苷（20、40、80 mg/kg）后能不同程度地有效降低急性以及亚急性气道高反应模型的气道阻力及IL-17A的水平。穿山龙总皂苷具有作为一种治疗气道高反应性药物的潜在价值，可能为支气管哮喘的治疗提供新的手段。

Abstract:: The Con-saponins of Dioscoreae Nipponicae (CDN) is the extract of traditional Chinese medicine, named Chuanlong, which can inhibit airway inflammation in animal models of asthma, but it has not been reported whether it has influence on airway hyperresponsiveness (AHR) that is the hallmark of asthma. Here, we studied the effect of CDN on the ozone-induced AHR in mice and the underlying mechanism. Firstly, mice were exposed to 2 ppm ozone to establish animal models of either acute or subacute AHR, which was verified by changes in airway resistance measured by FlexiVent. In addition, the total cell count and the counts of different cell populations in the bronchoalveolar lavage fluid (BALF) were determined under light microscope. The concentrations of interleukin-17A (IL-17A) in the BALF and lung tissue homogenate were detected by enzyme- linked immunosorbent assay (ELISA). The results demonstrated that inhalation of CDN (80 mg/kg, 40 mg/kg, 20 mg/kg) into mice could effectively reduce airway resistance and IL-17A levels. This suggests that CDN may be used as a potential bronchodilatory drug in asthma therapy.